Pacira BioSciences (FRA:82P) FCF Margin % : 27.68% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Pacira BioSciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pacira BioSciences's Free Cash Flow for the three months ended in Mar. 2024 was €42.6 Mil. Pacira BioSciences's Revenue for the three months ended in Mar. 2024 was €153.7 Mil. Therefore, Pacira BioSciences's FCF Margin % for the quarter that ended in Mar. 2024 was 27.68%.

As of today, Pacira BioSciences's current FCF Yield % is 11.32%.

The historical rank and industry rank for Pacira BioSciences's FCF Margin % or its related term are showing as below:

FRA:82P' s FCF Margin % Range Over the Past 10 Years
Min: -4.93 Med: 9.66 Max: 20.67
Current: 20.64

During the past 13 years, the highest FCF Margin % of Pacira BioSciences was 20.67%. The lowest was -4.93%. And the median was 9.66%.

FRA:82P's FCF Margin % is ranked better than
91.52% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.61 vs FRA:82P: 20.64

Pacira BioSciences FCF Margin % Historical Data

The historical data trend for Pacira BioSciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences FCF Margin % Chart

Pacira BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

14.34

9.13

14.75

17.28

20.67

Pacira BioSciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															7.84	23.66	25.04	25.26	27.68

Competitive Comparison of Pacira BioSciences's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacira BioSciences's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's FCF Margin % falls into.

Pacira BioSciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pacira BioSciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	127.91	/	618.955
	=	20.67 %

Pacira BioSciences's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	42.564	/	153.748
	=	27.68 %

Pacira BioSciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacira BioSciences (FRA:82P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (FRA:82P) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PCRX:USA

Address

5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609

Website

https://www.pacira.com

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.

Pacira BioSciences (FRA:82P) Headlines

No Headlines